Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;12(3):173-81.
doi: 10.1016/j.micinf.2009.12.001. Epub 2010 Feb 1.

Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity

Affiliations
Review

Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity

Martin Rowe et al. Microbes Infect. 2010 Mar.

Abstract

Persistent viruses have mechanisms for modulating the host immune responses that are essential for achieving a lifelong virus-host balance while minimizing the viral pathogenicity. Here we review some of the immune-modulating mechanisms evolved by the ubiquitous but potentially oncogenic Epstein-Barr virus, with particular emphasis on the molecular mechanisms of genes interfering with HLA class I antigen presentation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic comparing the modulation of HLA-I antigen presentation by (A) HCMV and (B) EBV gene products.
Fig. 2
Fig. 2
Residues in BGLF5 that, when mutated, affect both DNase and host-shutoff function (D203S; red), or selectively affect DNase (S280L; blue) or shutoff functions (K231M; yellow). The purple shaded regions of the BGLF5 cartoon structure represent the DNase catalytic core. The green shaded regions are the non-catalytic core domains mainly comprising the N-terminal domains, where in mutations selective for shutoff function are clustered in the KSHV SOX protein . The structure of the BGLF5 protein was taken from PDB ID: 2W45 (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Similar articles

Cited by

References

    1. Callan M.F., Steven N., Krausa P., Wilson J.D., Moss P.A., Gillespie G.M., Bell J.I., Rickinson A.B., McMichael A.J. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 1996;2:906–911. - PubMed
    1. Haque T., Wilkie G.M., Taylor C., Amlot P.L., Murad P., Iley A., Dombagoda D., Britton K.M., Swerdlow A.J., Crawford D.H. Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436–442. - PubMed
    1. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., Brenner M.K., Heslop H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet. 1995;345:9–13. - PubMed
    1. Rowe M., Kelly G.L., Bell A.I., Rickinson A.B. Burkitt's lymphoma: the Rosetta stone deciphering Epstein–Barr virus biology. Semin. Cancer Biol. 2009;19:377–388. - PMC - PubMed
    1. Rickinson A.B., Kieff E. Epstein–Barr virus. In: Knipe D.M., Howley P.M., editors. Fields Virology. Walters Kluwer/Lippincott, Williams & Wilkins; Philadelphia: 2007. pp. 2655–2700.

Publication types

MeSH terms

Substances